Pfizer and Astellas abandon efforts to expand Xtandi into breast cancer
admin 28th July 2017 Uncategorised 0There is troubling news for Pfizer and cancer med Xtandi, a shared asset it picked up in its $14 billion deal last year for Medivation. Pfizer and partner Astellas have given up their trials of Xtandi in breast cancer, cutting off an expansion that might have boosted sales of the blockbuster drug.
More: Pfizer and Astellas abandon efforts to expand Xtandi into breast cancer
Source: fierce